anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
1528956 Phenylalkanoic acid derivative HOMMEL AG 7 Oct 1975 [8 Oct 1974 (2)] 41050/75 Heading C2C The invention comprises compounds of the formula where R 1  is isobutyl or ethoxy, R 2  is ethyl or phenyl and R 3  is hydroxy, amino, alkoxy of 1-8 carbon atoms or a group of the formula where R 4  is alkylene optionally interrupted by an oxygen atom and R 5  and R 6  are H or alkyl or, together with the nitrogen atom to which they are attached, represent an optionally substituted heterocyclic ring, and salts thereof. Compounds wherein R 3  is hydroxy may be prepared by hydrolysing the corresponding cyanide. Compounds wherein R 3  is amino may be prepared by hydrolysing the corresponding cyanide under mild conditions or by amidizing the corresponding acid. Compounds wherein R 3  is amino, alkoxy of 1-8 carbon atoms or may be prepared by reacting the corresponding acid or a functional derivative thereof with the appropriate compound of the formula R 3 OH. The products may be converted into salts. The compounds exhibit antiinflammatory, analgesic, antitussive and anti-pyretic activity.
Group 2 implants without keratinized mucosa (KM). Alveolar mucosa (AM) directly present around the implant.
Inflammation is an important contributor to excess cardiovascular risk and progressive renal injury in people with chronic kidney disease (CKD). Dysregulation of the innate and adaptive immune system is accelerated by CKD and results in increased systemic inflammation, a heightened local vascular inflammatory response leading to accelerated atherosclerosis, and dysfunction of the cardiac and renal endothelium and microcirculation. Understanding and addressing the dysregulated immune system is a promising approach to modifying cardiorenal outcomes in people with CKD. However, targeted pharmacotherapies adopted from trials of non-CKD and cardiorheumatology populations are only beginning to be developed and tested in human clinical trials. Pharmacotherapies that inhibit the activation of the NOD-like receptor protein 3 inflammasome and the downstream cytokines interleukin-1 and interleukin-6 are the most well-studied. However, most of the available evidence for efficacy is from small clinical trials with inflammatory and cardiorenal biomarker endpoints, rather than cardiovascular event endpoints, or from small CKD subgroups in larger clinical trials. Other pharmacotherapies that have proven beneficial for cardiorenal endpoints in people with CKD have been found to have pleiotropic anti-inflammatory benefits including statins, mineralocorticoid receptor antagonists, sodium-glucose cotransporter 2 inhibitors, and glucagon-like peptide-1 agonists. Finally, emerging therapies in CKD such as interleukin-6 inhibition, small-interfering RNA against lipoproteins, aryl hydrocarbon receptor inhibitors, and therapies adopted from the renal transplant population including mammalian target of rapamycin inhibitors and T regulatory cell promoters may have benefits for cardiorenal and inflammatory endpoints but require further investigation in clinical trials.
Death Receptor 3 (DR3) is a cytokine receptor of the Tumor Necrosis Factor receptor superfamily that plays a multifaceted role in both innate and adaptive immunity. Based on the death domain motif in its cytosolic tail, DR3 had been proposed and functionally affirmed as a trigger of apoptosis. Further studies, however, also revealed roles of DR3 in other cellular pathways, including inflammation, survival, and proliferation. DR3 is expressed in various cell types, including T cells, B cells, innate lymphocytes, myeloid cells, fibroblasts, and even outside the immune system. Because DR3 is mainly expressed on T cells, DR3-mediated immune perturbations leading to autoimmunity and other diseases were mostly attributed to DR3 activation of T cells. However, which T cell subset and what T effector functions are controlled by DR3 to drive these processes remain incompletely understood. DR3 engagement was previously found to alter CD4 T helper subset differentiation, expand the Foxp3+ Treg cell pool, and maintain intraepithelial γδ T cells in the gut. Recent studies further unveiled a previously unacknowledged aspect of DR3 in regulating innate-like invariant NKT (iNKT) cell activation, expanding the scope of DR3-mediated immunity in T lineage cells. Importantly, in the context of iNKT cells, DR3 ligation exerted costimulatory effects in agonistic TCR signaling, unveiling a new regulatory framework in T cell activation and proliferation. The current review is aimed at summarizing such recent findings on the role of DR3 on conventional T cells and innate-like T cells and discussing them in the context of immunopathogenesis.
INTRODUCTION: Keratoconus is a progressive disorder of the cornea that causes thinning (Sedaghat et al. in Sci Rep 11(1):11971, 2021), ectasia, and irregular astigmatism, resulting in poor visual acuity that cannot be corrected with standard sphero-cylindrical spectacle lenses. One feature distinguishing keratoconic corneas is ocular aberrations, manifesting up to five or six times the amount of higher-order aberrations than a normal, healthy eye. These aberrations can cause visual disturbances even at the very early stages of the disease.
METHODS: In the past, a diagnosis was derived from clinical symptoms, but technological advances have revealed multiple pre-clinical features, allowing for the differentiation between keratoconic and normal eyes at a much earlier stage. These include anterior and posterior corneal surface elevations, the corneal pachymetry profile, corneal epithelial patterns, wavefront aberration metrics, and corneal biomechanics (Sedaghat et al. in Sci Rep 11(1):11971, 2021).This review discusses the aberrations associated with keratoconus, how to measure them, and treatment methods to minimize their negative influence.
CONCLUSIONS: Early diagnosis can lead to early treatment and may allow for arresting progression, thereby improving the long-term prognosis. With the acceleration of refractive surgery, it is important to identify patients with keratoconus, as they are usually contraindicated for refractive surgery.
Medhod:Patients in the control group underwent routine practice of the clinic and this group was observed for 199 days. The care bundle for pressure injuries developed within the scope of the research was not applied. In the study group, in addition to routine clinical practice, the care bundle for pressure injuries developed for this study was applied for 105 days. Since the pressure ulcer originating from the operating room was seen until the 48th-72nd hour, the evaluations and interventions within the scope of the study were performed for three days, considering the operation day as the zeroth day for the control and study groups. A total of 190 patients, 122 in the control group and 68 in the study group, were included in the study.

The care bundle consisted of "skin care, positioning, early mobilization, nutrition, and fluid intake" interventions. In the study, first, the data of the control group and then the data of the study group were collected.

Data Collection Tools: The Patient Descriptive Information Form consists of sociodemographic data. The 3S OR Pressure Injury Risk Assessment Scale was used to identify patients at risk of developing OR pressure ulcers. Visual Analogue Scale was used to evaluate pain perception. The Visual Analog Scale was used to determine the fear of falling. General Comfort Questionnaire-Short Form was used to determine the comfort level. The National Pressure Ulcer Advisory Panel (NPUAP) 2016 Pressure Injury Staging System was used to assess and stage pressure ulcer development. Pressure Injury Areas and Stages Follow-up Registration Form; The form in which the pressure ulcer development status is recorded.
Patients will then be randomized into one of the two groups above. One group will receive a lumbar erector spinae block at L4 with 30ml of 0.375% ropivacaine with 50 mcg of dexmedetomidine before the procedure using ultrasound guidance. The second group will receive no peripheral nerve block to serve as the control. All patients receiving nerve blocks will have a printed image of the block thus to confirm proper spread of local anesthetic both cranially and caudally.
The application discloses an anti-IL-13R alpha 2 nano antibody and a coding sequence and application thereof. The protein sequence of the nanobody contains a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 1. SEQ ID NO: 2. SEQ ID NO: 3. SEQ ID NO: 4. SEQ ID NO: 5 or SEQ ID NO: 6. The anti-IL-13R alpha 2 nano antibody provided by the application is applied to CAR-T cell treatment, can effectively improve the killing effect on target cells with positive IL-13R alpha 2 expression, and therefore has wide application in antibody immunotherapy and cellular immunotherapy. The nano antibody has extremely strong tumor tissue permeability, so that the nano antibody has unique advantages in the treatment of solid tumors.
Disclosed herein are monoclonal antibodies (Mabs) against ricin toxin and its subunits. The Mabs were initially selected based upon their ability to bind to ricin and its individual subunits in a solid-phase enzyme-linked immunoassay (ELISA). Several candidates were selected for further evaluation, including their ability to inhibit ricin intoxication in vitro and for their utility as immunodiagnostic reagents. As disclosed herein, the Mabs may be used in immunoassays. Also disclosed, are use of the Mabs to inhibit ricin-mediated eukaryotic cell cytotoxicity in vitro, thereby indicating that these Mabs may be used to prevent and treat ricin intoxication in vivo. Kits comprising the Mabs are also disclosed.
Children are not eating a sufficient amount of fruit and vegetables to ensure optimal health and development. Interventions are needed to help increase fruit and vegetable intake from the early years of children's lives, to support the development of lifelong healthy eating habits and the acceptance of vegetables as an important element of a normal diet. Vegetables are often refused by young children due to their often-bitter tastes, and so efforts to increase children's intake of vegetables is a health priority. Vegetables are not commonly offered at breakfast time, which reduces the opportunities each day for vegetables to be part of children's routine diets. Therefore, it is important to understand whether children will be willing to eat - or at least try - vegetables when offered alongside a usual breakfast food (e.g., cereal or toast). Preschool children eat many meals in childcare settings therefore nurseries provide an ideal setting in which to test whether the addition of vegetables at breakfast is feasible and acceptable to both children and nursery staff. This research will recruit nurseries in the East Midlands, UK, to investigate whether children and nursery staff are willing and able to offer (and eat) vegetables at breakfast. The study will adopt a feasibility cluster randomised controlled trial design where nurseries will be randomly allocated to deliver the Veggie Brek intervention or usual breakfast every weekday for three weeks. There will be a baseline period and follow-up period of five days where vegetables will be offered to children at breakfast.

Data will also be collected to understand the nursery staff's views on the study and how easy/difficult the study's procedures were to implement (e.g., were instructions clear and could be followed, were there any barriers to offering vegetables at breakfast). This information will be used to inform the feasibility and acceptability of a later trial.
OBJECTIVE: Managing the risk of epileptic seizures in older adults is increasingly important as the population ages. Leukotriene receptor antagonists (LTRAs) are commonly used to treat asthma or allergic rhinitis. Preclinical studies suggest that LTRAs have antiepileptic effects; however, few population-based etiological studies on this topic have been available. Our study explored whether LTRAs reduce hospitalization risk associated with epileptic seizures in older individuals with asthma or allergic rhinitis.
METHODS: We conducted a new-user design analysis using the Shizuoka Kokuho database. We included all individuals aged 60-89 years who had at least one episode of allergic rhinitis or asthma during the study period. We compared individuals who newly started LTRAs with those who did not take LTRAs. Propensity score matching was used to balance the baseline characteristics of the participants. We compared the hazard ratios for seizure-related hospitalization between new LTRA users and non-users and performed subgroup analyses.
RESULTS: Our matched cohorts consisted of 64 724 new users and non-users of LTRAs who were aged 60-89 years and had asthma or allergic rhinitis. During the observation period, 377 (0.58%) and 595 (0.92%) incidents were observed in the LTRA new-user and non-user groups, respectively. The hazard ratio for seizure-related hospitalization was 0.75 (95% confidence interval [CI]: 0.62-0.92) in the LTRA new-user group compared with the non-user group. Subgroup analysis revealed that the hazard ratio was weak in diabetic patients (1.31; 95% CI: 0.72-2.38).
SIGNIFICANCE: This study indicated that LTRAs reduced seizure-related hospitalization in older adult patients with allergic rhinitis or asthma. We could not evaluate the severity and related diseases of epileptic seizures during LTRAs. Further studies, including observational studies, detailed multicenter prospective studies, and clinical trials, are needed to validate these findings.
PLAIN LANGUAGE SUMMARY: This study examined if leukotriene receptor antagonists (LTRAs), commonly used for asthma or allergies, could lower seizure risk in older adults. Analyzing health records of 60-89 year-olds with asthma or allergies, we found a reduced rate of seizure-related hospitalizations in those starting LTRAs, though this was not as evident in diabetic patients. Our results suggest potential benefits of LTRAs in preventing seizures in older adults with respiratory issues, but further research is needed to confirm these findings.
NEW MATERIAL:A modified human epithelial cell growth factor expressed by the formula. USE:Antiulcer agents, curing agents for wounds and burns and remedies for corneal ulcer. PREPARATION:For example, a human epithelial cell growth factor (hEGF) is modified by using a genetic site mutational method to provide a DNA capable of coding a modified hEGF expressed by the formula in which (32)Ile is converted into (23)Phe. The resultant DNA is subsequently linked to a vector to form a recombinant plasmid containing a DNA region capable of coding the modified hEGF. The formed recombinant plasmid is then inserted into a microorganism such as Escherichia coli. transformation thereof is carried out to culture the transformed recombinant microbial cells. After culturing, the microbial cells are removed by centrifugation and ammonium sulfate is added to the supernatant. The resultant mixture is subjected to gel filtration to confirm a fraction containing the modified hEGF by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Ammonium sulfate is subsequently added to the fraction to afford precipitates, which are then dissolved in water, further subjected to gel filtration and purified to provide the modified hEGF expressed by the formula.
The control group of the Randomized Controlled Trial (RCT) was composed of 39 womens (between 18-49 years old) randomly assigned to the control group who are BMI was between 25.0-29.9 or BMI was between ≥30.0 according to the risk rating scales. A standard obesity training consisting of a single session was scheduled for the control group.
Kidney transplant recipients (KTR) are at an increased risk of developing Pneumocystis jirovecii pneumonia (PCP), especially during the first year after transplantation. This is the first reported pediatric KTR, with chronic kidney disease (CKD) secondary to kidney dysplasia and vesicoureteral reflux, who developed refractory and symptomatic hypercalcemia 5 years after transplantation. The hypercalcemia was resistant to treatment with intravenous hyperhydration, furosemide, and a low-calcium diet. A respiratory tract infection due to PCP treated with trimethoprim-sulfamethoxazole did not improve calcium levels. Due to the hypercalcemic symptom burden for the patient, a single dose of subcutaneous denosumab was used to achieve sustained clinical and biochemical improvement, without any severe adverse events. This case highlights the potential use of denosumab as a treatment option in pediatric KTR with refractory hypercalcemia related to PCP. Further study of denosumab in young people with CKD or kidney transplants is needed before routine use can be recommended.
No intervention will be carried out. The control group is selected by randomization from a pool of over-80s followed up by General Practitioners in the same cities who have been available to be involved in the study. Each GP provided a list of patients which 10 names have been selected from by randomization. The total pool consisted of approximately 8500 individuals. The sample was made up of 690 selected patients of which 83 (12.02%) refused to participate in the study.
BACKGROUND: The Kuwaiti and Qatari populations have a high prevalence of obesity, a major risk factor for various metabolic disorders. Previous studies have independently explored mitochondrial DNA (mtDNA) variations and their association with obesity in these populations. This study aims to investigate the role of mtDNA haplogroups and variants in obesity risk among these Gulf populations.
METHODS: Whole exome sequencing data from 1,112 participants (348 Kuwaitis and 764 Qataris) were analyzed for mtDNA variants. Participants were classified as obese or non-obese based on body mass index (BMI). Association analyses were performed to examine the relationship between mtDNA haplogroups and obesity, adjusting for covariates such as age and sex.
RESULTS: Haplogroup R was found to be protective against obesity, with an odds ratio (OR) of 0.69 (p = 0.045). This association remained significant after adjusting for age and sex (OR = 0.694; 95% CI: 0.482-0.997; p = 0.048). Several mtDNA variants, particularly those involved in mitochondrial energy metabolism, showed nominal associations with obesity, but these did not remain significant after correcting for multiple testing.
CONCLUSION: Haplogroup R consistently demonstrates a protective association against obesity in both Kuwaiti and Qatari populations, highlighting its potential as a biomarker for obesity risk in the Gulf region. However, further research with larger sample sizes is needed to validate these findings and clarify the role of mtDNA variants in obesity.
Each session will last 15 minutes, taking place 2 days a week, over a period of 4 weeks. Prior to training, the exercise protocol will be carried out. Prior to the start of the intervention, the exercises to be performed will be explained to the participants and it will be verified that they are capable of performing them correctly.
PROBLEM TO BE SOLVED: To obtain the subject preparation low in hygroscopicity and excellent in a characteristic for releasing nitrendipine having a calcium-antagonizing action and useful as a therapeutic agent for hypertension and angina by mixing the nitrendipine with a sugar alcohol, crushing the mixture and subsequently processing the crushed product into the preparation. SOLUTION: (A) Nitrendipine and (B) a sugar alcohol (e.g. a pharmacologically inactive sugar alcohol such as D-mannitol or xylytol) are mixed with each other, and preferably subsequently crushed. The compound B is preferably added in an amount of 0.5-10 pts.wt. per pt.wt. of the component A.
A system (10) is disclosed for gathering, processing, storing and reporting pharmacy data. Data from individual pharmacies is transmitted regularly to a data repository via an electronic communications network (45). Upon receipt at the data repository, the data first must pass through an access security screen (80) wherein data failing to meet predetermined criteria are rejected. If the data are determined to be valid, it is added to a data warehouse database by a computer data server (55). Authorized users may issue requests to the data repository based on current and/or historical data. Such requests may be made at any time via the electronic communications network (45) to create reports based on current data. The user first sends a request to the data repository for access. Once access to the data repository is granted, the user is able to obtain various types of information residing within the data warehouse (50). The amount and types of data available to the user may be limited by the user's predetermined security level clearance (80) and need-to-know, in order to protect patient privacy. The data may be presented to the user in a variety of predetermined report formats (90), as established by the type of data and the function of the user.
PURPOSE: To obtain an ibuprofen suspension liquid having improved stability of ibuprofen, eliminating or alleviating an irritating feeling and bitterness during administration. CONSTITUTION: This ibuprofen-containing suspension liquid comprises menthol or menthol and an essence of a crude medicine. An antiseptic and a sweetener are completely dissolved in an aqueous solution having pH 2 to pH 5 in which a pH adjuster (e.g. phosphoric acid buffer solution) is dissolved. The crude medicine, menthol and optionally an antiseptic and a thickening agent are uniformly dispersed into the solution, which is mixed with ibuprofen and other pharmacodynamically effective components, a spice, etc., if required. The solution is heat-treated at 55-65 deg.C for 10-20 minutes to give the objective ibuprofen suspension liquid. The amount of menthol for one administration is 1-45mg, the amount of the crude medicine [e.g. KANNZOU (root of Glycyrrhiza glabra)] is 0.0001-0.1wt.% based on the whole amount of a preparation and that of ibuprofen is 1-60mg/ml.